Deutsche Bank Ag\ Pds Biotechnology Corp Transaction History

Deutsche Bank Ag\

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$3.85 - $6.59 $23,515 - $40,251	-6,108 Reduced 28.39%	15,408 $61,000
Q4 2023 Feb 14, 2024	BUY	$3.95 - $6.58 $17,541 - $29,221	4,441 Added 26.01%	21,516 $106,000
Q3 2023 Nov 09, 2023	BUY	$4.8 - $6.4 $72,451 - $96,601	15,094 Added 761.94%	17,075 $86,000
Q2 2023 Aug 14, 2023	BUY	$5.03 - $9.9 $9,964 - $19,611	1,981 New	1,981 $9,000
Q4 2020 Feb 16, 2021	SELL	$1.91 - $2.67 $38,732 - $54,144	-20,279 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$1.67 - $4.67 $33,865 - $94,702	20,279 New	20,279 $47,000
Q2 2020 Aug 13, 2020	SELL	$0.65 - $2.6 $424 - $1,697	-653 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$0.67 - $3.04 $437 - $1,985	653 New	653 $0

4.06M

253K

70.4K

Ticker PDSB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,458,700
Market Cap $41.8M
Description
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.